BioSignal

Weekend deep dive: who really owns the West's drug pipeline? Everyone watches the FDA calendar. The real signal is upstream. I mapped the 13 biggest China-out licensing deals of the last ~24 months. Left: who discovered it. Right: who's selling it. ~$94B flowed West.

Everyone is watching the FDA's stance on rare disease biomarkers, and Disc Medicine ($IRON) just hit a major wall. Despite using an Accelerated Approval voucher, the FDA rejected Bitopertin for EPP, triggering a 20% workforce reduction and a pivot to P3 data. The FDA’s issue? The "limited" 40% reduction in PPIX levels wasn't enough to predict clinical benefit. This creates a massive opening for Chinese hematology players moving into the global orphan drug space. The takeaway: The FDA is tightening the screws on Accelerated Approvals. "Mechanistic plausibility" is no longer a substitute for hard clinical outcomes in the rare disease space. $IRON $XBI $IBB $VRTX

The "Golden Age" of Chinese siRNA has arrived. In just 23 days, three domestic biotechs have secured out-licensing deals worth over $6.8B with GSK, Madrigal, and Genentech. This isn't just about cash—it's about Big Pharma validating that Chinese delivery platforms (GalSTAR, LEAD) are now peer-level with Alnylam and Ionis. The most aggressive move? Madrigal Pharmaceuticals ($MDGL). Just after launching the first MASH drug (Rezdiffra), they’ve bet $4.4B on Ribo’s GalSTAR platform to create the "next-gen" combination therapy. They are engineering the future of liver disease by silencing the genetic drivers that pills can’t touch. The "China discount" is evaporating as these platforms prove they can engineer out the toxicity issues of Western predecessors. $688221.SH $MDGL $GSK $RHHBY $XBI $IBB

ASCO GI 2026 UPDATE: The "Toxicity Problem" in Solid Tumor CAR-T might just be solved. Everyone is watching Carsgen ($2171.HK) for CLDN18.2, but private contender Immunofoco just posted data that challenges the leader. They presented IMC002 (Nanobody CAR-T) for Gastric Cancer: • 66.7% ORR (High Efficacy) • 1 Patient in Complete Remission (CR) >60 weeks • The Kicker: 0% Grade 3+ CRS and 0% Neurotoxicity. Competitors have struggled to keep this target safe. Immunofoco’s VHH design just proved it’s possible. If you are long Astellas ($ALPMY) or Carsgen, watch this Phase 3 trial closely. The bar has been raised. $2171.HK $ALPMY $LEGN $BNTX $XBI $IBB

The "China Price Shock" has officially arrived in Cell Therapy. Biosyngen has just launched the first NMPA-approved Stem Cell drug for GVHD (Elmy-Mitosel), and the pricing strategy is aggressive. • Cost per dose: ~$2,700 USD (19.8k RMB) • Full Course: ~$22,000 USD They are explicitly marketing this as 1/70th the price of Western equivalents. This is a direct threat to the terminal value of $MESO (Mesoblast) and $INCY in the Asian market. Standard MSC therapies are being commoditized rapidly. The Western Defense: High-complexity innovation. Note that $OMER (Omeros) successfully secured FDA approval for Yartemlea in Dec '25 for TA-TMA. The only way to survive this pricing buzzsaw is to own novel targets (like MASP-2) rather than generic cell lines. $OMER $MESO $INCY $XBI $IBB

The "Keytruda Cliff" (2028 LOE) is the single biggest bear case on Merck. At #JPM26, Management just dismantled that thesis. Key updates from the deck: • 20+ new launches projected to generate >$70B by 2030. • This guidance was revised UP by $20B vs last year. • 80 active Phase 3 studies currently running. • Top assets: Winrevair (PAH) and Enflonsia (RSV). If $MRK hits these numbers, the patent cliff is a non-event. The pipeline isn't just replacing revenue; it's doubling the opportunity. $MRK $BMY $PFE $XBI $XLV

M&A SUPER-CYCLE LOADING: The Biotech freeze is officially thawing. The XBI has doubled from its April lows to hit $125, signaling that "Smart Money" is positioning for a massive 2026. The Catalyst? "Buy or Die." Big Pharma is facing a $47 Billion revenue cliff over the next 4 years due to patent expirations. They have no choice but to acquire growth. The Data (H2 2025 Surge): • M&A Velocity: 28 deals >$50M concluded (up 87% YoY). • The China lifeline: 62 US-China cross-border partnerships signed. Western Pharma is increasingly relying on Chinese labs for early-stage assets. The Risk/Reward Matrix: While "FDA Instability" remains a high-level threat (Score: 4/5), the "M&A Opportunity" score has hit a perfect 5/5. The market has shifted from "Survival Mode" to "Shopping Mode." Watch for small-caps with validated Phase 2 data—they are the prime targets. $XBI $IBB $NVO $SNY